China BioPharma Issues Profile on TheAsianInvestor.com.ISELIN, N.J. -- Techedge Inc. (OTCBB OTCBB
See OTC Bulletin Board (OTCBB). :TEDG) announced that China BioPharma, Ltd. has issued a company profile on Chinese investment website The Asian Investor.
Investors can view the company report by going to www.theasianinvestor.com
Peter Wang commented, "The Company is pleased to make this first step in launching our investor awareness Investor Awareness is knowledge the investment community has of a company.  It can be looked at like this: “Do investors know about your company?” If the answer is “yes,” then it could be said that the company has “good investor awareness” campaign for China BioPharma, Ltd., as one of China's largest non-government owned human vaccine production companies. The Company is involved in the research and production of human vaccines for highly contagious diseases such as Bird Flu bird flu: see influenza.
or avian influenza
viral respiratory disease, mainly of birds including poultry and waterbirds but also transmissible to humans. , EHF EHF
extremely high frequency
Noun 1. EHF - 30 to 300 gigahertz
extremely high frequency
radio frequency - an electromagnetic wave frequency between audio and infrared , and a number of Influenza viruses."
About China BioPharma
China BioPharma, which owns majority rights to Tianyuan Bio-pharmaceutical Co., Ltd., established in 1989, is one of China's largest non-governmental owned vaccine research manufacturers and is the first in China confirmed to GMP GMP (guanosine monophosphate): see guanine. standard. The company's current products consist of vaccines for epidemic hemorrhagic fever epidemic hemorrhagic fever
An acute viral hemorrhagic fever characterized by headache, high fever, sweating, thirst, photophobia, coryza, cough, myalgia, arthralgia, and abdominal pain with nausea and vomiting. (EHF) and influenza with high reputation and market-occupying rate. The vaccines for both epidemic hemorrhagic fever and influenza virus have been awarded the National New Product Prize and National Tech Progress Prize.
Tianyuan Bio-pharmaceutical Co., Ltd. plans to establish the production of 3 to 5 new products to its research portfolio of vaccines, with 3 major in the series of aspects of bacterial, virus, and viral vaccines, having already accomplished a batch of technical achievements with autonomous intellectual property. With its recently completed production facility that is the largest and best human-vaccine production facility in China, it is also the nation's main vaccine production base whenever there is an epidemic disease outbreak in the region, such as with SARS, or Avian H5N1 Influenza (bird flu). The company currently has around 140 employees.
For fiscal year 2005, Tianyuan Bio-pharmaceutical Co., Ltd. realized $9 million in sales, with a net profit of $1.5 million for the year, un-audited. The company is in the final process of completing independent audits to US GAAP GAAP
See: Generally Accepted Accounting Principles
See generally accepted accounting principles (GAAP). standards, which should be available for public review shortly.
About Techedge Inc.
The Company has recently repositioned itself to focus at opportunities in the fast growing bio-pharmaceutical sector in China. Techedge Inc. recent acquisition of China BioPharma Limited (CBP CBP
competitive protein binding. ), a Cayman Island company, which has majority ownership rights to Tianyuan Bio-pharmaceuticals Co. Ltd., is based out of Zhejiang Province, and the acquisition is pending Chinese government's final approval.
For more information on their current vaccines please visit www.ty-pharm.com
FORWARD-LOOKING STATEMENT forward-looking statement
A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. DISCLAIMER
Some of the statements made in this press release discuss future events and developments, including our future business strategy and our ability to generate revenue, income and cash flow, and should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. These "forward-looking" statements can generally be identified by words such as "expect," "anticipate," "believe," "estimate," "intend," "plan," and similar expressions. These statements involve a high degree of risk and uncertainty that exists in the Company's operations and business environment and are subject to change based on various factors that could cause actual Company results, performance, plans, goals and objectives to differ materially from those contemplated or implied in these forward-looking statements. Actual results may be different from anticipated results for a number of reasons, including the Company's new and uncertain business model, uncertainty regarding acceptance of the Company's products and services and the Company's limited operating history.